ASH 2024 Review: Key Updates in Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

M. Gallogly

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

ASH 2024 Insights: Incorporating Nivolumab and Brentuximab Vedotin I…

2024 ASH Annual Meeting Insights Hub

A. LaCasce

ASH 2024 Insights: Pembro Maintenance instead of ASCT for Pts With R…

Memorial Sloan Kettering Cancer Center

A. Moskowitz

ASH & ISHL 2024 Summary: Key Clinical Questions & Highlights in cHL

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

2024 ASCO® Annual Meeting Insights Hub

P. Johnson

Treatment Updates and Management of Hodgkin Lymphoma

Integrity CE

A. Niu, D. Wallace, M. Cortese

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

FL Updates: Is There a Standard 1L Treatment?

SOHO Brazil 2024

B. Kahl

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Landmark Clinical Trial Insights: SWOG S1826 for Advanced Stage cHL …

OncoPharm

J. Bossaer

Clinical Application of Practice-Changing SWOG S1826 Trial: Nivo+AVD…

Moffitt Cancer Center

Y. Zhang, B. Shah, J. Chavez, M. Jain, S. Gaballa

Standards of Care and Future Directions in FL

Martin Dreyling

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

Emerging and Current Treatment for Hodgkin Lymphoma in 2024

Indy Hematology Review

S. Ansell

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu